erythema multiforme/tyrosine

Koblingen er lagret på utklippstavlen

ArtiklerKliniske studierPatenter

Velg sorteringstype

6 resultater

Crizotinib-associated erythema multiforme in a lung cancer patient.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Crizotinib is an oral small-molecule anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor for the treatment of ALK-positive non-small-cell lung cancer (NSCLC). A 63-year old woman with postoperative relapsed ALK-positive NSCLC was treated with crizotinib. Erythema multiforme (EM) occurred one

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

There are currently several options for tyrosine kinase inhibitor as a systemic therapy for metastatic renal cell carcinoma (mRCC). The successful control of adverse events caused by such drugs, along with eliciting long-term maximum effect, are the major issues with respect to the treatment

Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was

Immunohistochemical characterization of cutaneous drug eruptions by STI571.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND STI571, a selective BCR-ABL tyrosine kinase inhibitor, is a promising new drug for chronic myelogenous leukemia (CML). However, the drug has been reported to be associated with adverse cutaneous drug eruptions with high frequency. OBJECTIVE In this study, the characteristics of the

Imatinib mesylate-induced lichenoid drug eruption.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists

Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Although the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for EGFR gene mutation-positive non-small cell lung cancer is well established, optimal dosing remains to be established, especially in elderly or frail patients.To

Bli med på
facebooksiden vår

Herbal & Natural Medicine

Den mest komplette databasen med medisinske urter støttet av vitenskap

Fungerer på 55 språk
Urtekurer støttet av vitenskap
Urtegjenkjenning etter bilde
Interaktivt GPS-kart - merk urter på stedet (kommer snart)
Les vitenskapelige publikasjoner relatert til søket ditt
Søk medisinske urter etter deres effekter
Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter

Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning